Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
Non-small Cell Lung Cancer, Small Cell Lung Cancer, Carcinoid
About this trial
This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring non-small cell lung cancer, NSCLC, small cell lung cancer, SCLC, carcinoid, thymic cancer, lung cancer, radiation therapy, radiotherapy, proton therapy
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically documented NSCLC, SCLC, thymic tumors, or carcinoid tumors
- Patients not receiving concurrent chemotherapy
- Patients that are eligible for concurrent treatment with biologic agents (epidermal growth factor receptor [EGFR] or vascular endothelial growth factor [VEGF] inhibitors) will be eligible for the study.
Exclusion Criteria:
- Prior radiotherapy to the chest
- Life expectancy <6 months
- Pregnancy
Sites / Locations
- University of Texas MD Anderson Cancer Center
Arms of the Study
Arm 1
Experimental
Proton Therapy
The radiation prescription dose ranges from 45 Gy in 3 Gy fractions to 60 Gy in 4 Gy fractions. Patients will be assigned to receive 1 of 3 doses of radiation therapy, based on when they joined the study. The first group of at least 3 participants will receive the lowest total radiation dose. If the first dose is tolerated well by the first group of participants in this study, then the next group of participants will receive the second, higher dose of radiation. If this dose is tolerated, then a third group will be treated at the highest dose.